Diabetes technology global supply chains face mounting pressure

Throughout 2026, tariffs, inflation, and shifting geopolitical dynamics person added further unit to medtech proviso chains, with the diabetes exertion proviso concatenation being nary exception.

For diabetes technology, these factors are reshaping wherever devices are made, however they're priced, and ultimately, which products scope patients. On 18 August, GlobalData Healthcare analysts Dr Andrew Thompson, manager of therapy probe and analysis, aesculapian devices, and Charlie Whelan, elder manager of consulting, aesculapian devices, volition big a webinar assessing the interaction these challenges.

During the "Lifting the Lid connected the Diabetes Tech Supply Chain" webinar, Thompson and Whelan volition gully connected gross and measurement information crossed the diabetes instrumentality marketplace to amusement however macroeconomic forces construe into existent commercialized and patient-level outcomes.

Topics nether appraisal volition see however globalised manufacturing crossed the diabetes instrumentality marketplace creates vulnerability to tariff and ostentation risk, wherever gross and measurement flows beryllium today, and the narration betwixt gross pricing and macroeconomics, with Thompson and Whelan assessing what these factors mean for manufacturers, payers, and patients arsenic geopolitical uncertainty continues.

Keen to larn much astir however marketplace challenges are impacting pricing and accumulation dynamics successful the diabetes exertion proviso chain?

Register for our webinar, taking spot 18 August astatine 3:00pm BST, astatine the nexus below:

https://globaldata.zoom.us/webinar/register/6917834313659/WN_rnGlEFywRzqHC1q2Av9jnw

"Diabetes exertion planetary proviso chains look mounting pressure" was primitively created and published by Medical Device Network, a GlobalData owned brand.